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Abstract
Background: Individuals with Down syndrome (DS) have increased mortality and are also at increased risk of celiac
disease (CD). It is unknown if CD influences mortality in DS. In this study we examined the risk of death in
individuals with DS according to celiac status.
Methods: In this nationwide population-based cohort study, we first identified individuals with CD (diagnosed
1969–2008) through small intestinal biopsy report data showing villous atrophy (Marsh stage III) from Sweden’s 28
pathology departments. Celiac individuals were then matched with up to five reference individuals from the
general population. In these cohorts we identified individuals with DS using International Classification of Disease
codes (ICD) registered in the Swedish Patient Register (includes inpatients and hospital-based outpatients), the
Medical Birth Register, and the Register of Congenital Malformations. Of 29,096 individuals with CD, 201 (0.7%) had
DS compared to 124 of the 144,522 reference individuals (0.09%). Data on mortality were obtained from the
Swedish Cause of Death Registry. Hazard ratios (HRs) for death were calculated using Cox regression.
Results: During follow-up, there were seven deaths among individuals with DS and CD (7/201, 3.5%) as compared
with 14 deaths among DS individuals without a record of CD (14/124, 11.3%). Adjusting for potential confounders,
CD did not influence the risk of death in DS (HR = 1.36; 95%CI = 0.33–5.59). Cardiovascular death occurred in two
individuals with CD and three individuals without CD, while death from malignancy occurred in one individual with
CD and two individuals without CD.
Conclusion: While both DS and CD have been linked to increased risk of death, this study found no excess
mortality in DS patients with a concurrent diagnosis of CD, however confidence intervals were wide.
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Background
Down syndrome (DS, trisomy 21) is the most frequent
chromosomal abnormality in the US, with 1 in about 700
liveborn children having DS [1]. Individuals with DS are at
increased risk of death, both overall and specifically from
congenital heart defects, dementia and leukemia as com-
pared with individuals without DS [2, 3]. However, in many
economically developed countries there has in the last de-
cades been markedly improved survival in DS patients. In
the US, the median survival increased from 25 years in
1983 to 49 years in 1997 [3]. This increased life expectancy
in DS patients is believed in large part to be attributed to
advances in medical management including early detection
and treatment of comorbid conditions, such as improved
provision of cardiac surgery for children with DS with
congenital heart defects [3, 4].
Celiac disease (CD) is an immune-mediated disorder
that occurs in about 1–2% of the Western population
and which is triggered by exposure to gluten in genetic-
ally susceptible individuals [5]. CD has been linked to an
increased risk of death in most [6], but not all, studies
[7]. Common causes of death include cardiovascular
disease and cancer [8]. CD has also been associated with
a number of disorders, including type 1 diabetes [9] and
mood disorders [10, 11].
Since the 1970s there have been reports on an associ-
ation between DS and CD, and the largest study to date
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in this field [12] found a 6-fold increased risk of biopsy-
verified CD in individuals with DS. Today, the leading
medical guidelines on DS and CD recommend CD
screening in individuals with DS [13–15]. As more and
more individuals with DS are diagnosed with CD, we
were motivated to examine if concurrent CD influences
the risk of death in DS.
We hypothesized that CD would be associated with an
increased risk of death in patients with DS.
Methods
In this nationwide population-based cohort study, we
first identified individuals with CD through small intes-
tinal biopsy report data. Government agencies matched
each individual with CD with up to five controls from
the general population. In these cohorts we then identi-
fied individuals with DS using data from national health-
care registries.
Through Cox regression we calculated Hazard ratios
(HRs) for death in individuals with DS and concurrent
CD as compared with DS individuals without a CD
diagnosis.
Study participants
In 2006–2008 we collected small intestinal biopsy
reports from all of Sweden’s 28 pathology departments
(biopsies per se had been carried out in 1969–2008).
Data were retrieved by local IT-personnel and included
information on personal identity number [16], biopsy
date, topography (duodenum or jejunum) and morph-
ology according to the Swedish SnoMed classification
(see our earlier paper for a detailed description [17]).
We defined CD as having villous atrophy (VA, in this
study equivalent to Marsh stage III [18]). While a posi-
tive serology was not a prerequisite for the celiac diag-
nosis, in a random sample of individuals, some 88%
were positive for CD serology at time of biopsy [17].
After the removal of duplicates and data irregularities, we
had data on 29,096 individuals with CD (identical to the
individuals in our earlier study on mortality in CD [8]).
Handling of matching
Individuals with CD were then matched for sex, age,
county and year of biopsy with up to five controls from
the Swedish Total Population Register [19]. We did not
restrict controls to individuals with a negative biopsy
since that would select a control population with more
comorbidity than the general population since healthy
people do not undergo routine biopsy. This matching
was originally carried out to construct two cohorts (one
with CD and one without CD). We then identified all in-
dividuals with DS from the CD cohort and from the
control cohort. Since DS occurs in less than one percent
of the population, we did not keep our initial matched
strata in the statistical analyses in the current study but
instead adjusted for potential confounders.
Down syndrome
We defined DS through any of the following ICD
(International Classification of Diseases) codes (ICD-8:
759,30 and 310–315,51; ICD-9: 758A; ICD-10: Q90)
in any of the registers: the Swedish National Patient
Register [20], the Medical Birth Register [21], and the
Register of Congenital Malformations [22].
The Swedish National Patient Register started in 1964,
became nationwide in 1987 and includes hospital-based
outpatient care since 2001 [20]. The positive predictive
value of most diagnoses is 85–95%, and it is estimated to
cover >99% of all non-psychiatric health care in Sweden.
The Swedish Medical Birth Register started in 1973 and
includes > 98% of all births in Sweden. The National
Register of Congenital Malformations collects data on
severe malformations and chromosomal abnormalities
since 1964. According to the National Board of Health
and Welfare, holder of the national health registers in
Sweden, the combined data from multiple registers en-
able a close to complete identification of individuals with
DS, including all three genetic variants of DS: trisomy 21
caused by meiotic non-disjunction, mosaicism and trans-
location. The Patient Register allows identification of DS
also for individuals born before 1973. A DS diagnosis
can be recorded at any age when a patient seeks health-
care (i.e. not only at birth).
Mortality
We used data from the Swedish Cause of Death Register
to ascertain overall mortality and cause-specific mortality.
Covariates
Data on socioeconomic status (according to the Euro-
pean Socioeconomic Classification: six categories with
missing data fit into a separate category [23]) and educa-
tion level (four a priori categories) [23] were obtained
from the government agency Statistics Sweden. Other
covariates included country of birth (Nordic versus not
Nordic), year of CD diagnosis (1989 and earlier, 1990–
1999, 2000 and later) and age at CD diagnosis (0–1.99;
2–9.99; 10–39.99; 40+ years). Data on type 1 diabetes
were obtained from the Swedish Patient Register (see
Additional file 1).
Statistics
We used Cox regression with years since study entry as
the time metric to estimate the HR for death in patients
with DS. We used a staggered entry statistical approach
since the original study sample included individuals at
date of biopsy and matched controls who were alive at
the corresponding date. Follow-up then ended with date
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of death, emigration or end of study (Dec 31, 2009). As
described above we broke the matching of our original
study sample since DS only occurs in a very small pro-
portion of participants (and to find several DS patients
in a stratum consisting of one CD patient and five con-
trols is extremely unlikely), and instead adjusted for po-
tential confounders. Therefore, HRs were adjusted for
sex, age at celiac diagnosis (or corresponding date of in-
clusion as a control), calendar period at first biopsy with
CD, socioeconomic status, level of education, country of
birth and type 1 diabetes.
Pre-planned analyses included HRs according to calen-
dar period at first celiac biopsy (1969–1989; 1990–1999;
2000–2009), sex and age. We present stratified HRs for
individuals with CD diagnosed in childhood (0–15 years)
versus adulthood (16+ years).
A power calculation showed that our study could de-
tect (at 0.05 significance and 80% power) a 2.26-fold in-
creased risk of death in patients with both DS and CD
compared to those with DS only.
We used SPSS 22 (SPSS, Inc. Chicago, IL, USA)
and R survival package for the analyses. Statistical sig-
nificance was defined as 95% confidence intervals
(CIs) for risk estimates not including one and a two-
sided p-value < 0.05.
Ethics
This study was approved by the Regional Ethical Review
Board in Stockholm, Sweden (June 4, 2006; 2006/633-
31/4). No individual consent was needed since data were
strictly register-based [24]. Data linkages with national
registers were initially performed by the government
agencies Statistics Sweden and the National Board of
Health and Welfare.
Results
Of 29,096 individuals with CD, 201 had DS (1 in 144).
Similarly, 124 of the 144,522 population-based controls
had DS (1 in 1165). Hence, this study included 325 indi-
viduals with a diagnosis of DS (Table 1). Only 5 individ-
uals with DS were born outside the Nordic countries.
More than 40% of individuals with CD were diagnosed
after the year 2000 (Table 1). The median year of CD
diagnosis was 1995.
During follow-up, there were seven deaths among indi-
viduals with DS and concurrent CD (7/201, 3.5%) as com-
pared with 14 deaths among DS individuals without a
record of CD (14/124, 11.3%). Of these seven individuals
with CD, four were females and three were males. Cardio-
vascular death occurred in two individuals with CD and
three individuals without CD, while death from malig-
nancy occurred in one individual with CD and two indi-
viduals without CD. The median age at death was 51 years
in patients with CD, and 61 years in those without CD.
Concurrent CD was not associated with risk of death
in DS (adjusted HR [aHR] = 1.36; 95%CI = 0.33–5.59).
The neutral aHR despite the larger proportion of deaths
in DS individuals without CD was due to a skewed age
distribution among DS patients. Some 25% of DS pa-
tients without CD entered the study at the age of
40 years or later, compared to only 7% of DS patients
with concurrent CD (Table 1).
While none of the risk estimates were statistically sig-
nificant, the aHRs for death were low in DS individuals
with a diagnosis of CD in childhood (0.18; 95%CI =
0.02–1.85), and high in those with an adult CD diagnosis
(5.78; 0.76–43.9) (p for interaction between age and CD
was 0.018).
Since there was only 1 death in DS individuals with
CD diagnosed before 1989, and 1 death from 2000 and
onwards (5 died between 1990 and 1999), we did not
examine the risk of death according to CD status for
individual calendar periods.
Individual causes of death are presented in Table 2.
Discussion
In a nationwide cohort of more than 29,000 individuals
with biopsy-verified CD we identified approximately 200
individuals with a concurrent diagnosis of DS. Through
linkage with national register data we were able to exam-
ine the role of CD in mortality in DS. While our study
had limited power, our data argue against CD influen-
cing mortality risk in DS.
DS has large phenotypic variation, with some features
occurring in all individuals with DS, including learning
disability, craniofacial stigmata and hypotonia in early
Table 1 Characteristics of patients with Down syndrome
Celiac disease Not Celiac disease
Total 201 124
Year of birth (median; range) 1958; 1942–1994 1943; 1921–1991
Year of death (median; range) 2002; 1997–2011 2005; 1999–2010
Females (%) 97 (48.3) 82 (66.1)
Males (%) 104 (51.7) 42 (33.9)
Not Nordic country of birth (%) 3 (1.5) 2 (1.6)
Type 1 diabetes (%) 1 (4.8) 12 (3.9)
Age, at study entry (years)
0–1.99 (%) 45 (22.4) 27 (21.8)
2–9.99 (%) 71 (35.3) 19 (15.3)
10–39.9 (%) 71 (35.3) 47 (37.9)
≥ 40 (%) 14 (7.0) 31 (25.0)
Calendar year at study entry
− 1989 (%) 10 (5.0) 28 (22.6)
1990–99 (%) 102 (50.7) 44 (35.5)
2000– (%) 89 (44.3) 52 (41.9)
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infancy [25]. DS is frequently associated with congenital
heart defects, early-onset dementia and childhood
leukemia. Apart from CD, other autoimmune diseases
such as type 1 diabetes or thyroid disorders are common
in DS patients [26, 27]. To identify such associated dis-
eases, Swedish children with DS are followed at pediatric
outpatient clinics at least once per year, while adult DS
patients often are seen biannually in primary care. Over-
all, health supervision of individuals with DS has im-
proved over the last decades, being one factor for the
improved life expectancy seen in the population with DS
[4]. Still, earlier population-based data have found that
individuals with DS have an overall 11-fold increased
risk of death, with an excess cause-specific mortality
from infectious diseases, heart disease and dementia etc
[2]. However, the potential influence of concurrent CD
on DS mortality has previously not been examined.
The pathogenetic link between DS and CD is not fully
understood. In general, the genetic susceptibility to CD
is believed to be shared between human leukocyte anti-
gen (HLA) genotypes on chromosome 6p21 and a large
number of genes outside the HLA loci [28]. However,
because individuals with DS have a similar distribution
of HLA genotypes as the general population [28] candi-
date genes in DS have been searched among immune-
related non-HLA loci. Two of the suggested candidate
genes (interferon receptor 1 [IFNAR1] and interferon re-
ceptor 2 [IFNAR2]), indeed located on chromosome 21,
encodes the receptor to the pro-inflammatory cytokine
interferon-alpha, which is believed to play an important
role in the intestinal immune response in CD [29].
This study has some strengths and limitations. We
used three different independent national registers to
identify individuals with DS. Together, these registers
should have high sensitivity for DS. Although the accur-
acy of the DS diagnosis per se has not been examined in
the Swedish national registers, it should be high, consid-
ering that the positive predictive value for other diagno-
ses in the Swedish National Patient Register is usually
85–95%. During follow-up, 21 individuals with DS died,
and among the causes of death were typical causes in
patients with DS (such as heart disease, dementia, and
chronic leukemia), although numbers were too small to
run cause-specific HRs. While the HR for death in DS
individuals with an adult diagnosis of CD was not statis-
tically significant (HR = 5.78), this finding may suggest
that DS individuals with long-standing undiagnosed CD
may be a group at increased risk. However, insufficient
statistical power (there were only 21 deaths among indi-
viduals with DS) meant an excess risk could not be for-
mally confirmed.
We used small intestinal biopsy data from all 28 path-
ology departments in Sweden to identify CD [17]. Dur-
ing the study period, more than 95% of all
gastroenterologists and pediatricians performed a small
intestinal biopsy before a CD diagnosis [17], and hence
the use of pathology data should yield a high sensitivity
for a CD diagnosis. Similarly, the specificity for CD
should be high, since other causes of villous atrophy
than CD are rare in Sweden. In a manual review of path-
ology reports in more than 1500 patient charts, the most
common comorbidity mentioned was inflammatory
bowel disease (Crohn’s disease or ulcerative colitis)
which occurred in 0.3% of those with villous atrophy
[17]. Biopsy reports were based on an average of 3 tissue
specimen [30], which should detect 95% of all villous at-
rophy. When Swedish pathologists examined blinded
samples of villous atrophy, they accurately graded 90%
of these as villous atrophy. While we did not have data
on symptoms in all patients with CD, in a subset of indi-
viduals undergoing patient chart validation (n = 118),
79% had gastrointestinal symptoms at diagnosis [17].
This is consistent with symptom data of other series of
celiac patients [31].
This nationwide study included more than 200 indi-
viduals with DS and CD. Still, given the relative rarity of
DS and concurrent CD we cannot rule out that we have
failed to observe a true difference in excess mortality
due to lack of study power. An alternative explanation is
that the small excess mortality in CD is difficult to de-
tect in DS patients who already have a high relative risk
of death. Another limitation of this study includes our
lack of data on dietary adherence in celiac patients with
DS hence this study does not examine the role of a
gluten-free diet in DS. However, a recent study by our
group found that mucosal healing (often a strong indica-
tor of dietary adherence) did not influence mortality
after CD diagnosis [32].
Table 2 Causes of death among patients with Down syndrome
Celiac disease Not celiac disease
Total 7 14
Chronic leukemia 1 1
Dementia 1
Heart disease or atherosclerosis 2 3
Liver cirrhosis 1
Down syndromea 2 4
Neurodevelopmental disorder 1
Brain tumor 1




aDiagnostic codes for underlying syndromes are often recorded as the
underlying cause of death in the Swedish Cause of Death Register. In Sweden,
however, the causes of death in individuals with DS have not been validated
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Regrettably, we also lacked data on other clinical
characteristics in order to decipher whether CD was
diagnosed due to symptomatic disease or as a result of
CD screening. During the time of study (up to 2008),
there were in Sweden no national guidelines for CD
screening in DS, and clinicians were instead advised to
have a high awareness of CD- related manifestations
and, if present, offer serological testing. Therefore, we
cannot rule out some degree of misclassification of CD
(i.e. false-negative) if not all patients with DS were
screened for CD. The current Swedish medical care
program for DS recommends repeated CD screening in
children, but not adults, with DS. This explains the
lower age in DS patients with CD (as opposed to those
with only DS), since general screening of DS patients
have been carried out especially in later years and in
younger individuals. This is also why the adjusted rela-
tive risk for death was neutral despite a much lower
absolute prevalence of death in DS + CD patients ((3.5%)
compared to patients with DS only (11.3%).
Conclusion
In conclusion, we found no excess mortality in DS pa-
tients with a concurrent diagnosis of CD. CD does not
seem to be a significant risk factor for death in patients
with DS.
Additional file
Additional file 1: Appendix. Description: contains data on histopathology
classification used in this study, and a list of international classification of
disease (ICD) codes to identify type 1 diabetes. (DOC 41 kb)
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